166 related articles for article (PubMed ID: 36878567)
41. Cost-effectiveness of cervical cancer prevention in Central and Eastern Europe and Central Asia.
Berkhof J; Bogaards JA; Demirel E; Diaz M; Sharma M; Kim JJ
Vaccine; 2013 Dec; 31 Suppl 7():H71-9. PubMed ID: 24332299
[TBL] [Abstract][Full Text] [Related]
42. [Health technology assessment report: HPV DNA based primary screening for cervical cancer precursors].
Ronco G; Biggeri A; Confortini M; Naldoni C; Segnan N; Sideri M; Zappa M; Zorzi M; Calvia M; Accetta G; Giordano L; Cogo C; Carozzi F; Gillio Tos A; Arbyn M; Mejier CJ; Snijders PJ; Cuzick J; Giorgi Rossi P
Epidemiol Prev; 2012; 36(3-4 Suppl 1):e1-72. PubMed ID: 22828243
[TBL] [Abstract][Full Text] [Related]
43. The projected timeframe until cervical cancer elimination in Australia: a modelling study.
Hall MT; Simms KT; Lew JB; Smith MA; Brotherton JM; Saville M; Frazer IH; Canfell K
Lancet Public Health; 2019 Jan; 4(1):e19-e27. PubMed ID: 30291040
[TBL] [Abstract][Full Text] [Related]
44. Estimate of the global burden of cervical adenocarcinoma and potential impact of prophylactic human papillomavirus vaccination.
Pimenta JM; Galindo C; Jenkins D; Taylor SM
BMC Cancer; 2013 Nov; 13():553. PubMed ID: 24261839
[TBL] [Abstract][Full Text] [Related]
45. Genotype-specific high-risk human papillomavirus infections and risk factors for cervical dysplasia in women with human immunodeficiency virus in Germany: results from a single-center cross-sectional study.
Wagner A; Skof AS; Sehouli J; Richter R; Henrich W; von Weizsäcker K; Siedentopf JP; Chekerov R; Kaufmann AM; Rohr I
Int J Gynecol Cancer; 2022 Jun; 32(6):716-723. PubMed ID: 35354606
[TBL] [Abstract][Full Text] [Related]
46. Human papillomavirus testing in the prevention of cervical cancer.
Schiffman M; Wentzensen N; Wacholder S; Kinney W; Gage JC; Castle PE
J Natl Cancer Inst; 2011 Mar; 103(5):368-83. PubMed ID: 21282563
[TBL] [Abstract][Full Text] [Related]
47. Prevalence of human papillomavirus infection among women presenting for cervical cancer screening in Chile, 2014-2015.
Balanda M; Quiero A; Vergara N; Espinoza G; Martín HS; Rojas G; Ramírez E
Med Microbiol Immunol; 2016 Dec; 205(6):585-594. PubMed ID: 27539577
[TBL] [Abstract][Full Text] [Related]
48. Knowledge and willingness of parents towards child girl HPV vaccination in Debre Tabor Town, Ethiopia: a community-based cross-sectional study.
Mihretie GN; Liyeh TM; Ayele AD; Belay HG; Yimer TS; Miskr AD
Reprod Health; 2022 Jun; 19(1):136. PubMed ID: 35689288
[TBL] [Abstract][Full Text] [Related]
49. [Impact of vaccination against oncogenic human papillomavirus on the incidence and mortality of cervical cancer in Germany].
Schneider A; Schwarz TF; Hammerschmidt T; Siebert U
Med Klin (Munich); 2007 Jul; 102(7):515-23. PubMed ID: 17634869
[TBL] [Abstract][Full Text] [Related]
50. Human papillomavirus vaccine as a new way of preventing cervical cancer: a dream or the future?
Mandic A; Vujkov T
Ann Oncol; 2004 Feb; 15(2):197-200. PubMed ID: 14760108
[TBL] [Abstract][Full Text] [Related]
51. Global burden of human papillomavirus and related diseases.
Forman D; de Martel C; Lacey CJ; Soerjomataram I; Lortet-Tieulent J; Bruni L; Vignat J; Ferlay J; Bray F; Plummer M; Franceschi S
Vaccine; 2012 Nov; 30 Suppl 5():F12-23. PubMed ID: 23199955
[TBL] [Abstract][Full Text] [Related]
52. Human papillomavirus: science and technologies for the elimination of cervical cancer.
Bosch FX
Expert Opin Pharmacother; 2011 Oct; 12(14):2189-204. PubMed ID: 21756205
[TBL] [Abstract][Full Text] [Related]
53. Prevention of human papillomavirus (HPV) infection and cervical cancer in China: how does HPV vaccination bring about benefits to Chinese women?
Liu X; Feng A; Cui Y; Tobe RG
Biosci Trends; 2013 Aug; 7(4):159-67. PubMed ID: 24056165
[TBL] [Abstract][Full Text] [Related]
54. Frequency of Human papillomavirus in women attending cervical cancer screening program in Chile.
Brebi P; Ili CG; Andana A; Menzel D; Lopez J; Guzman P; Melo A; Buchegger K; Roa JC
BMC Cancer; 2017 Aug; 17(1):518. PubMed ID: 28774281
[TBL] [Abstract][Full Text] [Related]
55. Diagnostic Performance of HPV E6/E7 mRNA and HPV DNA Assays for the Detection and Screening of Oncogenic Human Papillomavirus Infection among Woman with Cervical Lesions in China.
Wang HY; Lee D; Park S; Kim G; Kim S; Han L; Yubo R; Li Y; Park KH; Lee H
Asian Pac J Cancer Prev; 2015; 16(17):7633-40. PubMed ID: 26625774
[TBL] [Abstract][Full Text] [Related]
56. Human papillomavirus vaccines versus cervical cancer screening.
Stanley M
Clin Oncol (R Coll Radiol); 2008 Aug; 20(6):388-94. PubMed ID: 18538554
[TBL] [Abstract][Full Text] [Related]
57. Human papillomavirus prevalence and type-distribution, cervical cancer screening practices and current status of vaccination implementation in Central and Eastern Europe.
Poljak M; Seme K; Maver PJ; Kocjan BJ; Cuschieri KS; Rogovskaya SI; Arbyn M; Syrjänen S
Vaccine; 2013 Dec; 31 Suppl 7():H59-70. PubMed ID: 24332298
[TBL] [Abstract][Full Text] [Related]
58. Use of Multiplex Polymerase Chain Reaction for Detection of High-Risk Human Papillomavirus Genotypes in Women Attending Routine Cervical Cancer Screening in Harare.
Marembo T; Dube Mandishora R; Borok M
Intervirology; 2019; 62(2):90-95. PubMed ID: 31412350
[TBL] [Abstract][Full Text] [Related]
59. Rationale and design of a multicenter prospective cohort study for the eVALuation and monitoring of HPV infections and relATEd cervical diseases in high-risk women (VALHIDATE study).
Orlando G; Tanzi E; Chatenoud L; Gramegna M; Rizzardini G;
BMC Cancer; 2012 May; 12():204. PubMed ID: 22646512
[TBL] [Abstract][Full Text] [Related]
60. Roles of extended human papillomavirus genotyping and multiple infections in early detection of cervical precancer and cancer and HPV vaccination.
Song F; Yan P; Huang X; Wang C; Du H; Qu X; Wu R
BMC Cancer; 2022 Jan; 22(1):42. PubMed ID: 34991494
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
